Meta -analysis on lipid -lowering efficacy and safety of atorvastatin combining fenofibrate therapy on mixed hyperlipidemia
10.13699/j.cnki.1001-6821.2015.03.018
- VernacularTitle:阿托伐他汀联合非诺贝特治疗混合型高脂血症的Meta分析
- Author:
Gui-Lian ZHAO
1
;
Mei LIU
;
Xin-Lin LI
;
Li-Mei ZHAO
Author Information
1. 中国医科大学 附属盛京医院 药学部
- Keywords:
atorvastatin;
fenofibrate;
mixed hyperlipidemia;
meta-analysis
- From:
The Chinese Journal of Clinical Pharmacology
2015;(3):219-222
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the safety and efficacy of fenofibrate-atorvastatin combination therapy on mixed hyperlipidemia.Methods The databases of Cochrane Library, PubMed, WanFang, CNKI, CBM and VIP were retrieved with computers.Results There were totally 15 randomized contolled trials enrolled, involving 1980 cases.The results showed that the influence of combination therapy on TC, TG and HDL-C was much more significant than monotherapy and incidence of liver -associated adverse events and muscle -associated adverse events and total adverse events induced by combination therapy had no statistical difference compared with monotherapy.Besides, subgroup analysis indi-cated that the safety of fenofibrate plus standard-dose atorvastatin regi-men was similar to that of fenofibrate plus low-dose atorvastatin regimen [standard -dose: SMD =1.13, 95%CI(0.57, 2.24),P >0.05];low-dose:SMD=1.50, 95%CI(0.94, 2.39),P>0.05];the effects of fenofibrate combined with atorvastatin therapy significantly on the levels of TC and TG, and HDL -C were much more significant than monotherapy [SMD =-11.10, 95%CI( -18.44,3.77), P <0.05;SMD=-1.20, 95%CI(-1.28,1.12), P<0.05;SMD=0.694, 95%CI ( 0.587, 0.801 ) , P <0.05 ].Conclusion Fenofibrate combined with standard/low-dose atorvastatin treatment on mixed hyperlipidemia is generally safe and effective.
